Transposon Therapeutics Boosts Oncology Pipeline With Acquisition Of Novel Nucleoside Analogs

Transposon Therapeutics, a biotechnology company focused on developing innovative, orally administered therapies for neurodegenerative and age-related diseases, has announced its acquisition of a groundbreaking portfolio of nucleoside analogs from PrimeFour Therapeutics, Inc., a company dedicated to advancing cancer chemotherapeutic treatments.

This portfolio includes a diverse range of novel nucleoside analogs, each with distinct chemical properties. The most promising candidates within the collection are designed to induce "synthetic lethality" in cancers with specific genetic profiles, enabling precise targeting of the most vulnerable tumours while minimizing side effects. These compounds show potential in targeting cancers that harbour newly identified genetic biomarkers, particularly in pancreatic cancer and select other solid tumours, as well as hematologic cancers, thus offering a pathway for personalized treatment tailored to patients most likely to benefit.

Eckard Weber, M.D., founder and Chief Innovation Officer of Transposon, said in a statement, “This transaction allows us to build upon our leadership in developing first-in-class and best-in-class nucleoside reverse transcriptase inhibitors for neurodegenerative and autoimmune diseases, including ALS, PSP and Alzheimer’s disease. We are excited to expand our pipeline to include this portfolio of potent nucleoside chemotherapeutics with significant therapeutic potential against a variety of cancers. We look forward to advancing the lead compounds into preclinical development to target DNA-damage repair deficient cancers, such as pancreatic and colorectal cancers.”